Current Illinois CancerCare Clinical Trials

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Study Number: A021602

Study Summary:
This randomized phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

Status: Open

Study Coordinator(s)
  • Navigator Carrie, 309-243-3621, cmargis@illinoiscancercare.com
  • Drea, 309-243-3626 aogundipe@illinoiscancercare.com

Study Link

« Search Again